title: [Therapy of intraabdominal fungal infections].
abstract: Candida albicans is the fourth most germ that can be identified on surgical intensive care unit (SICU). During the course of severe peritonitis recognition of Candida is crucial for physicians but interpretation of Candida-positive microbiologic samples is difficult. The indication for antimycotic therapy requires differentiation between harmless contamination or severe invasive mycosis associated with high mortality. Therefore, we propose a four-stage classification. Stage I is the initial contamination of the abdominal cavity by Candida spp. Stage IIa is characterized by persistence of fungi in patients without risk factors, IIb with risk factors respectively. Stage III means histological evidence of Candida invasion into the peritoneal layer. Stage IV is a generalized infection with fungemia/fungal sepsis. We recommend antimycotic therapy in stage IIb or higher.
authors.affiliation: Klinik für Chirurgie, Universitätsklinikum Schleswig-Holstein, D-23538 Lübeck, Germany. kujath-luebeck@t-online.de
authors.forename: P
authors.initials: P
authors.lastname: Kujath
authors.forename: R
authors.initials: R
authors.lastname: Bouchard
authors.forename: J
authors.initials: J
authors.lastname: Nolde
authors.forename: J
authors.initials: J
authors.lastname: Scheele
mesh_terms: D034841:Abdominal Cavity / Q000382:microbiology; D000935:Antifungal Agents / Q000627:therapeutic use*; D002176:Candida albicans / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D013502:General Surgery; D006801:Humans; D007362:Intensive Care Units; D010538:Peritonitis / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000935:Antifungal Agents